IL23A and inflammatory bowel disease: These characteristics have induced many approaches to IBD therapy to inhibit both the IL-12 and IL-23 signaling pathways, such as the use of monoclonal antibodies targeting p40 [98] or through epithelial HIF-stabilization that regulate T helper cell populations via IL-12 cytokine family signaling [99].